Literature DB >> 32420091

Kallistatin correlates with inflammation in abdominal aortic aneurysm and suppresses its formation in mice.

Yuchen He1, Yanshuo Han2, Jia Xing3, Xiaoyue Zhai3, Shiyue Wang1, Shijie Xin1, Jian Zhang1.   

Abstract

BACKGROUND: Kallistatin (KS), encoded by SERPINA4, was suggested to play a protective role in many cardiovascular diseases. However, its role in the pathogenesis of abdominal aortic aneurysm (AAA) remains unclear. The aim of this study was to examine the potential association of KS with AAA pathogenesis.
METHODS: We examined KS (SERPINA4) expression in human AAA by PCR, immunohistochemistry, western blotting, and enzyme-linked immunosorbent assay (ELISA) and analyzed correlations between kallistain and clinical data. We then analyzed the effect of recombinant KS on AAA formation and the Wingless (Wnt) signaling pathway in a mouse AAA model developed by angiotensin II (AngII) infusion to apolipoprotein E-deficient (ApoE-/-) mice.
RESULTS: In AAA tissue samples, KS was significantly increased compared with samples from the control group (P<0.001, P<0.001, respectively). Clinically, decreased SERPINA4 expression in AAA tissue samples represented an increased rate of iliac artery aneurysm [odds ratio (OR): 0.017; P=0.040]. And decreased plasma KS level represented a high risk for rupture (OR: 0.837; P=0.034). KS inhibited AAA formation and blocked the Wnt signaling pathway in AngII-infused ApoE-/- mice.
CONCLUSIONS: The present study demonstrates that aberrant changes in KS expression occur in AAA. KS plays an important anti-inflammatory role and showed important clinical correlations in AAA. Decreased KS (SERPINA4) level is a risk factor of AAA rupture. Our pre-clinical animal experiments indicate that treatment with recombination KS suppresses AngII-induced aortic aneurysm formation and might be a new target for the drug therapy of AAA. 2020 Cardiovascular Diagnosis and Therapy. All rights reserved.

Entities:  

Keywords:  Abdominal aortic aneurysm (AAA); inflammation; serine proteinase inhibitors (SERPINs)

Year:  2020        PMID: 32420091      PMCID: PMC7225437          DOI: 10.21037/cdt.2019.12.08

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  34 in total

1.  Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation.

Authors:  Hang Yin; Lin Gao; Bo Shen; Lee Chao; Julie Chao
Journal:  Hypertension       Date:  2010-06-21       Impact factor: 10.190

Review 2.  Kallistatin: double-edged role in angiogenesis, apoptosis and oxidative stress.

Authors:  Julie Chao; Pengfei Li; Lee Chao
Journal:  Biol Chem       Date:  2017-11-27       Impact factor: 3.915

3.  Role of vascular endothelial growth factor-A in development of abdominal aortic aneurysm.

Authors:  Hidehiro Kaneko; Toshihisa Anzai; Toshiyuki Takahashi; Takashi Kohno; Masayuki Shimoda; Aya Sasaki; Hideyuki Shimizu; Toshiyuki Nagai; Yuichiro Maekawa; Koichi Yoshimura; Hiroki Aoki; Tsutomu Yoshikawa; Yasunori Okada; Ryohei Yozu; Satoshi Ogawa; Keiichi Fukuda
Journal:  Cardiovasc Res       Date:  2011-03-24       Impact factor: 10.787

Review 4.  ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation.

Authors:  Alan T Hirsch; Ziv J Haskal; Norman R Hertzer; Curtis W Bakal; Mark A Creager; Jonathan L Halperin; Loren F Hiratzka; William R C Murphy; Jeffrey W Olin; Jules B Puschett; Kenneth A Rosenfield; David Sacks; James C Stanley; Lloyd M Taylor; Christopher J White; John White; Rodney A White; Elliott M Antman; Sidney C Smith; Cynthia D Adams; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Raymond J Gibbons; Sharon A Hunt; Alice K Jacobs; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel
Journal:  Circulation       Date:  2006-03-21       Impact factor: 29.690

5.  Kallistatin antagonizes Wnt/β-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6.

Authors:  Jingmei Zhang; Zhirong Yang; Pengfei Li; Grant Bledsoe; Lee Chao; Julie Chao
Journal:  Mol Cell Biochem       Date:  2013-05-12       Impact factor: 3.396

6.  Novel role of kallistatin in vascular repair by promoting mobility, viability, and function of endothelial progenitor cells.

Authors:  Lin Gao; Pengfei Li; Jingmei Zhang; Makoto Hagiwara; Bo Shen; Grant Bledsoe; Eugene Chang; Lee Chao; Julie Chao
Journal:  J Am Heart Assoc       Date:  2014-09-18       Impact factor: 5.501

7.  Kallistatin reduces vascular senescence and aging by regulating microRNA-34a-SIRT1 pathway.

Authors:  Youming Guo; Pengfei Li; Lin Gao; Jingmei Zhang; Zhirong Yang; Grant Bledsoe; Eugene Chang; Lee Chao; Julie Chao
Journal:  Aging Cell       Date:  2017-05-24       Impact factor: 9.304

8.  Antagonizing Wnt pathway in diabetic retinopathy.

Authors:  Ling Zhao; Sherrina H Patel; Jacqueline Pei; Kang Zhang
Journal:  Diabetes       Date:  2013-12       Impact factor: 9.461

9.  Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis.

Authors:  Zhiyun Cheng; Yinghui Lv; Suqiu Pang; Ruyu Bai; Mingxi Wang; Shuyu Lin; Tianwen Xu; Duncan Spalding; Nagy Habib; Ruian Xu
Journal:  Acta Pharm Sin B       Date:  2015-04-07       Impact factor: 11.413

Review 10.  The Potential Role of Kallistatin in the Development of Abdominal Aortic Aneurysm.

Authors:  Jiaze Li; Smriti Murali Krishna; Jonathan Golledge
Journal:  Int J Mol Sci       Date:  2016-08-11       Impact factor: 5.923

View more
  1 in total

1.  Effects of hypercholesterolism on expansion of abdominal aortic aneurysm in rat model.

Authors:  Jong Seok Lee; Sun Cheol Park; Sang Dong Kim
Journal:  J Cardiothorac Surg       Date:  2021-12-27       Impact factor: 1.637

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.